New Drugs: Deucravacitinib for Plaque Psoriasis
Dr. Ted Rosen reports on the FDA’s recent approval of deucravacitinib, the first drug in its class for treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy and phototherapy. Ted Rosen, MD, FAAD Editor-in-Chief As the first drug in its class, deucravacitinib (Sotyktu, Bristol Myers Squibb) has received FDA […]